|
|
WuXi PharmaTech’s 2008 Meets Expectations, Though AppTec Disappoints
publication date: Mar 26, 2009
WuXi PharmaTech (药明康德) met, but didn’t beat, its 2008 financial guidance goals and admitted that its $151 million AppTec acquisition has not performed up to expectations. WuXi shut down AppTec’s US-based biologics manufacturing operations in December of 2008, saying it did not see any resurgence in that sector. However, AppTec’s biopharma and medical device testing business is continuing. WuXi Chairman and CEO Ge Li blamed AppTec’s disappointing performance on the larger economic crisis, which curtailed demand for contract biologics manufacturing. More details... Stock Symbol: (NYSE: WX)
|
ChinaBio® Events
ChinaBio® Partnering Forum 2012May 23-24, 2012 Suzhou, China >>More events...
Partner Events
 China Healthcare Investment Conference 2012March 13-15, 2012 Shanghai, China Shanghai CEO ConferenceMarch 28-29, 2012 Shanghai, China >>More details...
Other Events
China Pharmaceutical R&D SummitApril 23-26, 2012 Shanghai, China Biosimilars Asia 2012April 23-26, 2012 Shanghai, China Vaccines China 2012April 23-26, 2012 Shanghai, China
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners
![]()
|